Gradle 9.5.0 and its patch 9.5.1 bring clearer diagnostics, CI-resilient wrapper downloads, and long-awaited Kotlin DSL improvements.
A Science Advances study using Webb data finds Nereid's icy composition rules out a Kuiper Belt origin, making it the sole intact remnant of Neptune's primordial moon system.
Andreessen Horowitz leads a $250M Series C in Exa, valuing the AI-native search startup at $2.2B as it serves over 5,000 companies including Cursor, Cognition, and HubSpot.
Google Quantum AI and Google.org are funding five universities to develop quantum sensors and algorithms for molecular biology, targeting drug discovery and human health.
SIG-etcd has released the first beta of etcd 3.7.0, introducing streaming reads for large result sets, up to 2x faster lease operations, and the complete elimination of all v2 API code.
A patent-pending staining method developed at Oxford enables nanoscale imaging of battery binders, reducing internal ionic resistance by up to 40 percent and pointing toward faster-charging, longer-lasting EV batteries.
Apache Iceberg 1.11.0 arrives with at-rest encryption across all table files, Spark 4.1 and Flink 2.1 compatibility, and Deletion Vector write support for Flink.
Grafana Labs shipped version 13 at its annual conference in Barcelona, graduating dynamic dashboards and Git Sync to GA while delivering a rebuilt Loki that runs aggregation queries up to 10x faster.
The FTC settled its 2022 lawsuit against Kochava and subsidiary Collective Data Solutions, barring the companies from selling precise location data without affirmative express consent in the most significant U.S. enforcement action against a location data broker.
Waymo adds 200 square miles to five existing markets, reaching over 1,400 sq mi and positioning its autonomous fleet across six 2026 World Cup host cities.
Mozilla ships Firefox 151 on May 19, 2026, patching 25 security vulnerabilities and adding PDF merging, Document PiP, Web Serial API, and tighter fingerprinting controls.
Fractyl Health received authorization in the Netherlands to run the world's first clinical trial of an AAV-based GLP-1 gene therapy for type 2 diabetes, targeting patients who cannot sustain daily injections.